Eli Lilly And Co (NYSE:LLY) Major Shareholder Sells $28,478,600.00 in Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $138.92, for a total value of $28,478,600.00. Following the completion of the sale, the insider now directly owns 113,741,549 shares in the company, valued at approximately $15,800,975,987.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Thursday, January 9th, Lilly Endowment Inc sold 220,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $135.79, for a total value of $29,873,800.00.
  • On Tuesday, January 7th, Lilly Endowment Inc sold 32,645 shares of Eli Lilly And Co stock. The shares were sold at an average price of $132.90, for a total value of $4,338,520.50.
  • On Friday, December 20th, Lilly Endowment Inc sold 19,705 shares of Eli Lilly And Co stock. The shares were sold at an average price of $132.90, for a total value of $2,618,794.50.
  • On Tuesday, December 17th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $125.69, for a total value of $27,023,350.00.
  • On Monday, December 9th, Lilly Endowment Inc sold 10,962 shares of Eli Lilly And Co stock. The shares were sold at an average price of $119.70, for a total value of $1,312,151.40.
  • On Friday, December 6th, Lilly Endowment Inc sold 194,038 shares of Eli Lilly And Co stock. The shares were sold at an average price of $120.15, for a total value of $23,313,665.70.
  • On Wednesday, December 4th, Lilly Endowment Inc sold 210,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $119.77, for a total value of $25,151,700.00.
  • On Wednesday, November 27th, Lilly Endowment Inc sold 48,953 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.51, for a total value of $5,752,467.03.
  • On Monday, November 25th, Lilly Endowment Inc sold 109,318 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.60, for a total value of $12,855,796.80.
  • On Thursday, November 21st, Lilly Endowment Inc sold 108,264 shares of Eli Lilly And Co stock. The shares were sold at an average price of $115.14, for a total value of $12,465,516.96.

Shares of LLY stock traded up $1.43 on Tuesday, reaching $140.37. 176,562 shares of the stock were exchanged, compared to its average volume of 3,244,057. The stock has a market cap of $132.50 billion, a P/E ratio of 25.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.20. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. The firm has a 50 day moving average of $126.70 and a two-hundred day moving average of $115.12. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $139.99.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The business had revenue of $5.48 billion during the quarter, compared to the consensus estimate of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.39 EPS. On average, equities research analysts predict that Eli Lilly And Co will post 5.8 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.11%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

Several hedge funds have recently added to or reduced their stakes in LLY. Investors Research Corp raised its position in shares of Eli Lilly And Co by 5.6% in the 3rd quarter. Investors Research Corp now owns 1,764 shares of the company’s stock valued at $197,000 after acquiring an additional 93 shares during the period. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Eli Lilly And Co by 10.2% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 1,023 shares of the company’s stock valued at $113,000 after buying an additional 95 shares in the last quarter. FTB Advisors Inc. boosted its position in Eli Lilly And Co by 3.0% during the third quarter. FTB Advisors Inc. now owns 3,275 shares of the company’s stock worth $366,000 after purchasing an additional 95 shares during the period. Carnegie Capital Asset Management LLC boosted its position in Eli Lilly And Co by 1.9% during the third quarter. Carnegie Capital Asset Management LLC now owns 5,228 shares of the company’s stock worth $585,000 after purchasing an additional 97 shares during the period. Finally, Investors Asset Management of Georgia Inc. GA ADV boosted its position in Eli Lilly And Co by 0.7% during the third quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 14,035 shares of the company’s stock worth $1,570,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 76.45% of the company’s stock.

Several research analysts have weighed in on the company. UBS Group cut their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Morgan Stanley upgraded Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. boosted their price target on Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 price target on shares of Eli Lilly And Co in a report on Monday, December 2nd. Finally, Argus boosted their price target on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $135.67.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: S&P 500 Index

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.